Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
4.6
Journals
Pharmaceuticals
Special Issues
Prevention, Diagnosis and Treatment of Pediatric Diseases
share announcement

Prevention, Diagnosis and Treatment of Pediatric Diseases

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: closed (31 May 2021)

Special Issue Editor

Prof. Dr. Susanna Esposito

E-Mail Website
Guest Editor
Director of Pediatric Clinic, Pietro Barilla Children’s Hospital Director of Specialization School in Pediatrics Department of Medicine and Surgery, University of Parma Building 15, Via Gramsci 14, 43126 Parma, Italy
Interests: pediatrics; children; pediatric infectious diseases; vaccines; antinfective therapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The rapidity with which new information is acquired, which is useful for a more precise diagnosis and more effective prevention and treatment of diseases affecting children and adolescents, requires those who follow and monitor the health of the pediatric population, periodic updates that are easily accessible and of high quality. Furthermore, new technologies (e.g., telemedicine, artificial intelligence) have an increasingly significant impact today in drug development of pediatric patients with acute and chronic illness.

The aim of this Special Issue of Pharmaceuticals is to present a collection of articles that provide a current snapshot of the research in the pediatrics field. Manuscripts covering all aspects of research relating to medicinal chemistry and related drug sciences in pediatric diseases are welcome.

Dr. Esposito Esposito
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Pediatrics
  • Children
  • Pediatric diseases
  • Vaccines
  • Pediatric drugs

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

22 pages, 1663 KiB  
Review
State of the Art on Approved Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators and Triple-Combination Therapy
by Aniello Meoli, Valentina Fainardi, Michela Deolmi, Giulia Chiopris, Francesca Marinelli, Caterina Caminiti, Susanna Esposito and Giovanna Pisi
Pharmaceuticals 2021, 14(9), 928; https://doi.org/10.3390/ph14090928 - 15 Sep 2021
Cited by 21 | Viewed by 4976
Abstract
Cystic fibrosis (CF) is the most common life-limiting inherited disease in Caucasian populations, affecting approximately 80,000 people worldwide. CF is a complex multi-organ monogenic autosomal recessive disorder caused by a mutation in cystic fibrosis transmembrane conductance regulator (CFTR) gene. Since the [...] Read more.
Cystic fibrosis (CF) is the most common life-limiting inherited disease in Caucasian populations, affecting approximately 80,000 people worldwide. CF is a complex multi-organ monogenic autosomal recessive disorder caused by a mutation in cystic fibrosis transmembrane conductance regulator (CFTR) gene. Since the discovery of the CFTR gene in 1989, more than 2000 mutations have been identified so far and about 240 can cause CF. Until recently, the treatment for CF was aimed to prevent and manage the manifestations of CFTR dysfunction, primarily recurrent pulmonary infections and pancreatic exocrine failure. Over the past few decades, the therapeutic approach to CF has been revolutionized by the development of a new class of small molecules called CFTR modulators that target specific defects caused by mutations in the CFTR gene. CFTR modulators have been shown to change profoundly the clinical course of the CF, leading to meaningful improvements in the lives of a large proportion of people of CF heterozygous for F508del, especially if started in young children. Further studies are needed to extend the use of triple CFTR modulation therapy also for young children in order to prevent the irreversible effects of the disease and for patients with very rare mutations with a personalized approach to treatment. Full article
(This article belongs to the Special Issue Prevention, Diagnosis and Treatment of Pediatric Diseases)
►▼ Show Figures

Figure 1

14 pages, 263 KiB  
Review
New Antibiotics for the Treatment of Acute Bacterial Skin and Soft Tissue Infections in Pediatrics
by Nicola Principi, Alberto Argentiero, Cosimo Neglia, Andrea Gramegna and Susanna Esposito
Pharmaceuticals 2020, 13(11), 333; https://doi.org/10.3390/ph13110333 - 23 Oct 2020
Cited by 8 | Viewed by 3449
Abstract
Acute bacterial skin and soft tissue infections (aSSTIs) are a large group of diseases that can involve exclusively the skin or also the underlying subcutaneous tissues, fascia, or muscles. Despite differences in the localization and severity, all these diseases are due mainly to [...] Read more.
Acute bacterial skin and soft tissue infections (aSSTIs) are a large group of diseases that can involve exclusively the skin or also the underlying subcutaneous tissues, fascia, or muscles. Despite differences in the localization and severity, all these diseases are due mainly to Gram-positive bacteria, especially Staphylococcus aureus and Streptococcus pyogenes. aSSTI incidence increased considerably in the early years of this century due to the emergence and diffusion of community-acquired methicillin-resistant S. aureus (CA-MRSA). Despite the availability of antibiotics effective against CA-MRSA, problems of resistance to these drugs and risks of significant adverse events have emerged. In this paper, the present knowledge on the potential role new antibiotics for the treatment of pediatric aSSTIs is discussed. The most recent molecules that have been licensed for the treatment of aSSTIs include ozenoxacin (OZ), ceftaroline fosamil (CF), dalbavancin (DA), oritavancin (OR), tedizolid (TD), delafloxacin (DL), and omadacycline (OM). However, only OZ and CF have been licensed for use in children with aSSTIs, although the superiority of these antibiotics to those routinely used for the treatment of aSSTIs should be further demonstrated. Waiting for additional studies, OZ and CF should be prescribed for aSSTI treatment in the presence of the potential failure of old molecules. Full article
(This article belongs to the Special Issue Prevention, Diagnosis and Treatment of Pediatric Diseases)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop